Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,225 stopped studies mapped to Malignant Digestive System Neoplasm and descendants · 91% state a reason
Over the 2,225 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05223036 | Testing Obeticholic Acid for Familial Adenomatous Polyposis | Phase 2 | terminated | Feb 3, 2022 | National Cancer Institute (NCI) | Protocol has been completed prematurely due to poor accrual and study feasibility. | Enrollment / accrual |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate,… | — | suspended | Jul 9, 2021 | National Cancer Institute (NCI) | Due to slow accrual on this trial, we will allow sites time to work on close-out procedures and… | Enrollment / accrual |
| NCT03426371 | Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody… | Phase 3 | terminated | Feb 8, 2018 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Due to adjustments in our R\&D strategy, we are discontinuing the 140-III-01 study and initiating… | Sponsor / business decision |
| NCT02928627 | Clinical Significance of Hepatic and Circulating microRNAs miR-221 and miR-222 in… | — | terminated | Oct 10, 2016 | University of Aberdeen | The project did not progress as there were no findings available for the lab analysis of microRNA… | Other (stated, no rule matched) |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | University of Chicago | enrollment goal met pending determination of evaluable subjects | Enrollment / accrual |
| NCT06149741 | Defunctioning Left-sided Colostomy in Low Anterior Resection for Rectal Cancer(STOMALEFT) | N/A | terminated | Nov 29, 2023 | Umeå University | Logistical difficulties at study sites. 16/20 patients included. | Other (stated, no rule matched) |
| NCT04541381 | The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care | N/A | suspended | Sep 9, 2020 | University of Chicago | pending study amendment/re-design | Other (stated, no rule matched) |
| NCT05415917 | Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer… | Phase 2 | withdrawn | Jun 13, 2022 | Rutgers, The State University of New Jersey | No patients enrolled | Enrollment / accrual |
| NCT05494658 | Impact of Preoperative Oral Branched-chain Amino Acids on Reducing Postoperative Insulin… | N/A | terminated | Aug 10, 2022 | Sun Peng | The mid-term analysis of the study showed no significant difference between the two groups. | Other (stated, no rule matched) |
| NCT06653010 | Universal CAR-T Cells (REVO-UWD-01) for Metastatic Colorectal Cancer(Wondercel-UWD1) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | Early Phase 1 | suspended | Oct 22, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT06675513 | Autologous CAR-T Cells (WD-01) for Metastatic Colorectal Cancer | Early Phase 1 | suspended | Nov 5, 2024 | Wondercel Biotech (ShenZhen) | Because the implementation of the new regulation policy by the Chinese authority | Other (stated, no rule matched) |
| NCT02664389 | Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in…(PANEL) | N/A | terminated | Jan 27, 2016 | University Hospital, Rouen | Difficulty in enrolling patients | Enrollment / accrual |
| NCT05027425 | Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed… | Phase 2 | terminated | Aug 30, 2021 | University of Cincinnati | The study is closing due to low enrollment and feasibility of the study. | Enrollment / accrual |
| NCT06653192 | EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction… | N/A | suspended | Oct 22, 2024 | Hospital Universitari de Bellvitge | Class I Recall (Feb 2026): Boston Scientific issued a global recall for specific lots of AXIOS… | Other (stated, no rule matched) |
| NCT02908048 | Extracellular RNA Markers of Liver Disease and Cancer | — | terminated | Sep 20, 2016 | Mayo Clinic | Ran out of funds | Funding |
| NCT04034251 | Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for… | Phase 2 | terminated | Jul 26, 2019 | National Cancer Institute (NCI) | Scientific reprioritization. Closed per principal investigator discretion to prioritize enrollment… | Investigator |
| NCT05983133 | A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors | Phase 1 | terminated | Aug 9, 2023 | Seagen, a wholly owned subsidiary of Pfizer | The trial was terminated for strategic reasons. The decision was not based on any safety concerns | Safety / toxicity |
| NCT02072616 | Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.(CTC-Pancreas) | N/A | terminated | Feb 26, 2014 | University Hospital, Rouen | Analysis not possible at the stage | Other (stated, no rule matched) |
| NCT04481204 | New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or… | Phase 2 | withdrawn | Jul 22, 2020 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES… | N/A | suspended | Jun 18, 2021 | Rutgers, The State University of New Jersey | Pending Protocol amendment | Other (stated, no rule matched) |
| NCT07173374 | Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A…(SCART-P) | Phase 1 | suspended | Sep 15, 2025 | Shandong Cancer Hospital and Institute | The study was terminated early due to slow patient accrual. Enrollment was substantially lower than… | Enrollment / accrual |
| NCT05718882 | Lenvatinib Plus VIC-1911 in Lenvatinib-unresponsive or Lenvatinib-resistant HCC | N/A | terminated | Feb 8, 2023 | RenJi Hospital | The study was terminated because the originally planned VIC-1911 dose-escalation scheme (100 mg,… | Safety / toxicity |
| NCT06630325 | A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced… | Phase 2 | terminated | Oct 8, 2024 | OHSU Knight Cancer Institute | Loss of support. | Other (stated, no rule matched) |
| NCT04336202 | Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy(Whistle) | N/A | suspended | Apr 7, 2020 | Sir Mortimer B. Davis - Jewish General Hospital | Issues with applicator | Other (stated, no rule matched) |
| NCT05103904 | Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant | Phase 2 | terminated | Nov 2, 2021 | Emory University | Slow Accrual | Enrollment / accrual |
| NCT03876561 | "Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low…(CONTICARE) | N/A | terminated | Mar 15, 2019 | Nantes University Hospital | lack of inclusion | Other (stated, no rule matched) |
| NCT04101292 | Endoscopic Optical Imaging for Precision Oncology Treatment Applied to Colorectal Tumours… | N/A | withdrawn | Sep 24, 2019 | IHU Strasbourg | Problems with the provision of equipment encountered during the study could not be resolved, making… | Other (stated, no rule matched) |
| NCT04107766 | NOLA (NeuWave Observational Liver Ablation) Registry | — | terminated | Sep 27, 2019 | Ethicon, Inc. | Change in Company Strategy | Sponsor / business decision |
| NCT04387071 | CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers… | Phase 1 / Phase 2 | terminated | May 13, 2020 | University of Southern California | Study drug no longer available | Other (stated, no rule matched) |
| NCT05861947 | A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies(JIVAN) | Phase 1 | terminated | May 17, 2023 | Aurigene Discovery Technologies Limited | Patient recruitment problems | Enrollment / accrual |
| NCT06760702 | A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AUR 109…(TEJAS-2) | Phase 2 | terminated | Jan 7, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT07040059 | A Phase 1b/2 Clinical Trial Evaluating the Efficacy, Safety, Pharmacokinetics, and… | Phase 1 / Phase 2 | terminated | Jun 26, 2025 | Aurigene Discovery Technologies Limited | Patient recruitment problems. | Enrollment / accrual |
| NCT04600466 | Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer | — | terminated | Oct 23, 2020 | The University of Texas Health Science Center at San Antonio | PI leaving institution | Other (stated, no rule matched) |
| NCT02151019 | Pre-operative 3-DCRT vs IMRT for Locally Advanced Rectal Cancer(TRI-LARC) | Phase 1 / Phase 2 | terminated | May 30, 2014 | Cancer Trials Ireland | Due to futility | Efficacy / futility |
| NCT02872831 | Beacon BNX™ Endoscopic Ultrasound (EUS)-Needle vs SharkCore™ Needle | N/A | withdrawn | Aug 19, 2016 | Thomas Jefferson University | Principal Investigator let the institution prior to study initiation. | Investigator |
| NCT05518110 | PaTcH Study: A Phase 2 Study of Trametinib and Hydroxychloroquine in Patients With…(PaTcH) | Phase 2 | terminated | Aug 26, 2022 | Cancer Trials Ireland | Study terminated due to futility | Efficacy / futility |
| NCT05567835 | A Study of Total Neoadjuvant Chemotherapy With FLOT VS Standard Perioperative FLOT in…(TOGAR) | Phase 2 | terminated | Oct 5, 2022 | Baylor College of Medicine | Since activation, 3 subjects were enrolled but were ineligible for randomization to a treatment arm… | Enrollment / accrual |
| NCT07479381 | Colorectal Lesion Evaluation and Appropriate Resolution (CLEAR) Study(CLEAR) | — | terminated | Mar 18, 2026 | Harbinger Health | Study terminated per sponsor decision due to operational reasons. The termination was not a result… | Safety / toxicity |
| NCT06034197 | Fluorescent Probe VGT-309 to ID Cancerous Colorectal Lesions During Augmented Colonoscopy | Early Phase 1 | terminated | Sep 13, 2023 | Stephan Rogalla | The drug supply expired and the sponsor is unable to provide an updated supply. | Drug supply |
| NCT06152523 | Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer(MONAMI) | Phase 2 | withdrawn | Nov 30, 2023 | Assistance Publique - Hôpitaux de Paris | The study has been halted because the manufacturer can no longer supply the experimental treatment | Drug supply |
| NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor… | Phase 2 | withdrawn | Apr 6, 2026 | NGM Biopharmaceuticals, Inc | Study terminated by Sponsor | Other (stated, no rule matched) |
| NCT06692452 | Tazemetostat Plus CHOP in 1L T-cell Lymphoma | Phase 2 | withdrawn | Nov 18, 2024 | Eric Jacobsen, MD | Ipsen requested a temporary closure due to a safety concern. | Safety / toxicity |
| NCT03727633 | Hepatocellular Carcinoma on Cirrhosis With Child A/B7 and Hepatic Intra Arterial…(LIDA-BII) | Phase 2 | terminated | Nov 1, 2018 | University Hospital, Montpellier | Enrollement rythm low, funding body decision. | Enrollment / accrual |
| NCT02366819 | Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating… | Phase 4 | suspended | Feb 19, 2015 | University of Chicago | Pending data analysis | Other (stated, no rule matched) |
| NCT04234113 | Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With… | Phase 1 | terminated | Jan 21, 2020 | SOTIO Biotech AG | Due to lack of efficacy shown at the time of the interim analysis. | Efficacy / futility |
| NCT05188573 | EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset… | N/A | withdrawn | Jan 12, 2022 | ClearNote Health | Study not initiated. | Other (stated, no rule matched) |
| NCT04523389 | Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients(ExoColon) | — | terminated | Aug 21, 2020 | Centre Hospitalier Universitaire Dijon | As the laboratory due to carry out the biological analyses withdrew, the project did not go ahead | Other (stated, no rule matched) |
| NCT05131776 | EUS-guided Intra-tumour Injection of OncoSil for Locally Advanced Pancreatic Carcinoma. | Phase 2 / Phase 3 | terminated | Nov 23, 2021 | Chinese University of Hong Kong | Inadequate funding | Funding |
| NCT05240040 | Treat Primary and Metastatic Liver Tumors | — | withdrawn | Feb 15, 2022 | Methodist Health System | Resources | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated May 14, 2026source: clinicaltrials